Research · Sep 3, 2026
[SOLV] Solventum Thesis 2026: Dental Divestiture Tests Post-3M Spin Healthcare Refocus
Solventum Corporation (NYSE: SOLV) FY2025 revenue ~$8.2-8.4B (-1 to +2%) with adj. EPS ~$4.00-5.00 reflecting continued post-April 2024 3M spin transition + selected announced 2024-2025 Dental Solutions divestiture process (~$3-4B+ valuation expected) + selected Medical Surgical leadership ($4.1B; ~50% of revenue) + selected Health Information Systems AI coding/CDI tailwind + selected operational continuity under continued CEO Bryan Hanson (~2.5-year tenure pre-spin since April 2023). Leading global healthcare technology firm spun off from 3M Company on April 1, 2024 as the former 3M Healthcare segment ($8.2B revenue baseline). Selected post-spin standalone Solventum operations include selected ~120-year heritage as part of 3M's healthcare portfolio (dating to 3M's 1902 founding + Riker Laboratories 1962 acquisition + various healthcare M&A through ~120-year history). Selected post-spin Solventum independent operations + selected ~$8B+ debt assumed from 3M parent. Headquartered in Maplewood Minnesota; ~22,000+ employees globally with ~$8.2-8.4B revenue. Four reporting segments: Medical Surgical ~50% revenue ($4.1B — surgical solutions drapes + gowns + medical adhesives + advanced wound care including Tegaderm + Coban + selected ~30%+ wound care market share + sterilization indicators), Dental Solutions ~15% ($1.2B — dental restorative Filtek + orthodontic Clarity + dental adhesives + cementation; selected announced divestiture process 2024-2025 ~$3-4B+ valuation expected), Health Information Systems ~15% ($1.2B — clinical documentation 3M 360 Encompass + AI-powered coding/CDI computer-assisted CDI), Purification & Filtration ~20% ($1.7B — water + biopharma single-use filtration + industrial water). Dental divestiture: selected announced 2024-2025 strategic alternatives review targeting ~$3-4B+ valuation reflecting non-core dental positioning vs Medical Surgical + HIS + Purification core focus + selected ~3-4x revenue valuation reflecting category-leading dental materials brand + selected potential strategic acquirers including Henry Schein + Patterson Companies + dental specialty firms + private equity; divestiture proceeds expected for debt reduction (~$8B+ inherited 3M debt) + M&A in core focus areas + selected potential capital return. CEO Bryan Hanson since April 2023 (selected appointed by 3M to lead spin-off transformation; ex-Zimmer Biomet CEO 2017-March 2023 + ex-Medtronic Global Diabetes + various roles 1989-2017 ~30-year Medtronic career). Capital return: ~$1.16-1.32 quarterly dividend FY2025 (post-spin partial year initiation); modest buybacks; investment-grade Baa3/BBB- credit ratings; FCF $0.5-0.8B reflecting post-spin transition + interest expense. FY2026 thesis: Dental divestiture closing + post-3M separation completion + operating margin expansion + capital return resumption. Risks: Dental divestiture below $2.5B, post-spin transition disruption, Medtronic + Becton Dickinson competitive substitution, interest rate exposure on $8B+ debt.